HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV (HIV CoCo)
Sponsor: Gilead Sciences
This observational or N/A phase trial investigates COVID-19 and HIV-1-infection and is currently completed. Gilead Sciences leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
6 versions recorded-
Apr 2025 — Present [monthly]
Completed
-
Sep 2024 — Apr 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Oct 2023 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Mar 2023 — Oct 2023 [monthly]
Recruiting
▶ Show 1 earlier version
-
Sep 2022 — Mar 2023 [monthly]
Recruiting
First recorded
Mar 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
- NEAT ID Foundation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Bilbao, Spain , Bradford, United Kingdom , Bristol, United Kingdom , Brussels, Belgium , Derby, United Kingdom , Elche, Spain , Glasgow, United Kingdom , Logroño, Spain , London, United Kingdom and 5 more locations